◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

AC Immune SA (ACIU) Financial History

Name: AC Immune SA (ACIU) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-09-10

AC Immune SA (ACIU) operates in the Biotechnology industry and is headquartered in Lausanne, Switzerland with about 90 employees. Its market capitalization is roughly $274 million. In the fiscal year ended 2025-12-31, ACIU reported CHF 4M in revenue and (CHF 70M) in net income.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.

Interactive charts & full statements → Open the ACIU valuation workbench →

ACIU Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	CHF 4M	CHF 27M	CHF 15M	CHF 4M
Operating Income (EBIT)	(CHF 69M)	(CHF 52M)	(CHF 54M)	(CHF 71M)
Net Income	(CHF 70M)	(CHF 51M)	(CHF 54M)	(CHF 71M)

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ACIU Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Total Revenue	CHF 15M	CHF 1M	CHF 0M	CHF 1M	CHF 1M	—	—
Operating Income (EBIT)	CHF 1M	(CHF 15M)	(CHF 14M)	(CHF 16M)	(CHF 19M)	—	—
Net Income	CHF 2M	(CHF 15M)	(CHF 14M)	(CHF 16M)	(CHF 21M)	—	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ACIU Free Cash Flow History

ACIU Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CHF 154M	CHF 231M	CHF 183M	CHF 186M	—
Total Liabilities	CHF 109M	CHF 119M	CHF 22M	CHF 17M	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ACIU viewer.

Other Companies in Biotechnology

TRDA · Entrada Therapeutics, Inc. — $278 million
CAMP · CAMP4 THERAPEUTICS CORPORATION — $277 million
MSCL · Satellos Bioscience Inc. — C$276 million
MGNX · MacroGenics, Inc. — $275 million
PYXS · Pyxis Oncology, Inc. — $273 million
SRZN · Surrozen, Inc. — $268 million
AVXL · Anavex Life Sciences Corp. — $264 million
ALXO · ALX Oncology Holdings Inc. — $263 million

← ACIO All “A” companies ACIW →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.